Part of NephTimes
Charlotte RobinsonHyperkalemia | July 15, 2024
Could SZC use allow for quick and safe initiation and titration of MRAs and long-term optimal dosing for patients with HRrEF?
Read More
Charlotte RobinsonHyperkalemia | July 10, 2024
Authors described the case of a patient with BRASH syndrome-induced atrial fibrillation with a slow ventricular response.
Charlotte RobinsonHyperkalemia | July 9, 2024
What influence does hyperkalemia have on disease severity and mortality risk among patients admitted to the emergency room?
Charlotte RobinsonHyperkalemia | July 8, 2024
Researchers studied how race, ethnicity, and other demographic factors relate to the risk of recurrent hyperkalemia.
Charlotte RobinsonHyperkalemia | June 12, 2024
Transplant recipients often present with characteristics that may be associated with hyperkalemic renal tubular acidosis.
Charlotte RobinsonNKF Spring Clinical Meetings 2024 | May 29, 2024
Pooja Desai discussed a study examining short- vs long-term results of SZC therapy on hyperkalemia-related hospitalization.
Charlotte RobinsonHyperkalemia | April 24, 2024
Research has begun to question recommendations to restrict potassium with CKD to manage hyperkalemia.
Charlotte RobinsonWCN 2024 | April 18, 2024
Researchers studied the prevalence of hyperkalemia in patients at a facility in Durban, South Africa.
Charlotte RobinsonWCN 2024 | May 23, 2024
Researchers reported on real-world use of SZC for hyperkalemia in a cohort of Asian hemodialysis patients.
Charlotte RobinsonHyperkalemia | March 28, 2024
Potassium adsorbents lower serum potassium levels but their effects on mortality and rehospitalization rates were unclear.
Charlotte RobinsonHyperkalemia | March 27, 2024
Researchers sought to determine the palatability of SZC, patiromer, and S/CPS in patients with CKD and hyperkalemia.
Charlotte RobinsonHyperkalemia | March 27, 2024
Experts developed consensus statements for management of hyperkalemia in the Asia–Pacific region.
Victoria SochaHyperkalemia | February 5, 2024
The prevalence of hyperkalemia among individuals with chronic kidney disease (CKD) is 14% to 20%.
Victoria SochaHyperkalemia | February 5, 2024
Examining the effects of finerenone doses in patients with chronic kidney disease (CKD) and type 2 diabetes.
Victoria SochaChronic Kidney Disease | February 5, 2024
When dietary potassium intake was examined within quartiles, there was a nonlinear association with AAC.
Victoria SochaHyperkalemia | February 5, 2024
Both hyperkalemia and hypokalemia are associated with muscle paralysis and potentially fatal cardiac arrhythmias.
Victoria SochaHyperkalemia | February 5, 2024
There are few data available on the adverse effect of hyperkalemia on progression of chronic kidney disease (CKD).
Victoria SochaHyperkalemia | February 5, 2024
Patients with hyperkalemia treated with SCZ have a higher rate of continuation of RAAS inhibition.
Victoria SochaHyperkalemia | May 23, 2024
Examining whether administration of patiromer would reduce the number of significant arrhythmia events.
Victoria SochaHyperkalemia | February 5, 2024
Training an artificial intelligence algorithm that can detect hyperkalemia from the surface electrocardiogram.
Latest News

July 16, 2024